Anticancer agent 102

Cat. No.: HY-149062 CAS No.: 2914922-86-2 Molecular Formula: $C_{20}H_{19}F_{6}N_{3}O$

Molecular Weight: 431.37 Target: **Apoptosis** Pathway: **Apoptosis**

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

Product Data Sheet

BIOLOGICAL ACTIVITY

Description

Anticancer agent 102 is a derivative of tetracaine. Anticancer agent 102 has anti-cancer activity. Anticancer agent 102 induces apoptosis^[1].

In Vitro

Anticancer agent 102 (compound 2s; 24 and 48 h) has antitumor activity with IC $_{50}$ values of 299.4 μ M and 20.8 μ M against Colo-205 and HepG2 cells, respectively^[1].

Anticancer agent 102 (25 µM and 50 µM; 24 h) down-regulates the expression level of apoptotic protein PI3K and FoXO3a, upregulates the expression level of PTEN and FoXO1 in Colo-205 cells^[1].

Anticancer agent 102 (24 h) up-regulates Bax expression and induces caspase-3-dependent apoptosis in the HepG2 cell line

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Colo-205 and HepG2 cells
Concentration:	12.5, 25, 50, 100, 200, and 400 μM
Incubation Time:	24 and 48 hours
Result:	Inhibited cell growth in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:	Colo-205 cells
Concentration:	25 μM and 50 μM
Incubation Time:	24 hours
Result:	down-regulated the expression level of apoptotic protein PI3K and FoXO3a, up-regulated the expression level of PTEN and FoXO1 in Colo-205 cells.

REFERENCES

1]. M İhsan Han, et al. Design, Sy	ynthesis, and Anticancer Evaluation of	Novel Tetracaine Hydrazide	e-Hydrazones. ACS Omega. 2023 F	Feb 28;8(10):9198-9211.
	Caution: Product has not been fu			
		609-228-5909 CDr, Suite Q, Monmouth	E-mail: tech@MedChemExpre Junction, NJ 08852, USA	ss.com

Page 2 of 2 www.MedChemExpress.com